Hookipa Pharma Intrinsic Value Calculator – Gilead’s $21.25M Equity Investment Sends Hookipa Pharma Stock Soaring
December 22, 2023
🌥️Trending News
Hookipa Pharma ($NASDAQ:HOOK), Inc. is a biopharmaceutical company based in Vienna, Austria, focused on the development of therapies that use immunomodulatory viruses to treat cancer and infectious diseases. This is the single largest investment in the company’s history. Gilead’s equity investment has sent Hookipa Pharma’s stock soaring to new heights. The funds from Gilead’s investment will be used to advance Hookipa Pharma’s clinical programs and technical capabilities. It is expected that this influx of capital will bolster the company’s efforts to develop treatments for infectious diseases and cancer.
With Gilead’s help, Hookipa Pharma can continue to develop its innovative products and bring them to market faster. The $21.25 million equity investment from Gilead is a major milestone for Hookipa Pharma. It signals the continued growth of the company and boosts investor confidence in its potential. It remains to be seen how this investment will impact Hookipa Pharma’s future success, but its stock has certainly seen a dramatic surge in response to this news.
Market Price
On Thursday, HOOKIPA PHARMA experienced a major surge in stock price, opening at $1.0 and closing at $0.9. This was fuelled by Gilead Sciences’ equity investment of $21.25 million. This led to the stock price rising 52.7% from its prior closing price of 0.6, and helped to send the value of Hookipa Pharma soaring. The investment will provide Hookipa Pharma with funds to help with the development and commercialization of its clinical programs, such as its mRNA vaccines and immunotherapies for infectious diseases and cancer.
Additionally, it will aid in further clinical development of HOOKIPA’s T-cell therapies. This investment is seen as a major coup for the company, and is likely to have a positive impact on its future prospects. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Hookipa Pharma. More…
| Total Revenues | Net Income | Net Margin |
| 20.55 | -69.07 | -336.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Hookipa Pharma. More…
| Operations | Investing | Financing |
| -33.16 | -4.34 | 44.23 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Hookipa Pharma. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 164.01 | 68.96 | 1.13 |
Key Ratios Snapshot
Some of the financial key ratios for Hookipa Pharma are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.4% | – | -332.2% |
| FCF Margin | ROE | ROA |
| -182.5% | -41.1% | -26.0% |
Analysis – Hookipa Pharma Intrinsic Value Calculator
At GoodWhale, we have conducted an analysis of HOOKIPA PHARMA‘s fundamentals and have come to the conclusion that the fair value of a share in HOOKIPA PHARMA is around $1.8. This figure is an estimation based on our proprietary Valuation Line, which takes into account factors such as the company’s financial health, market trends and overall performance. Currently, HOOKIPA PHARMA shares are trading at $0.9, undervaluing the company by 48.6%. This provides investors with an opportunity to purchase shares at a below-market rate, potentially providing a significant return on investment. GoodWhale’s analysis of HOOKIPA PHARMA gives us confidence that investing in the company at its current rate will be a smart move for investors. More…
Peers
The company’s pipeline includes two clinical-stage product candidates, HB-201 and HB-202, which are being evaluated in Phase I and Phase II clinical trials, respectively. HOOKIPA Pharma Inc’s main competitors are Applied Genetic Technologies Corp, Heat Biologics Inc, and TC BioPharm (Holdings) PLC.
– Applied Genetic Technologies Corp ($NASDAQ:AGTC)
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company that develops transformative gene therapies for patients suffering from severe genetic diseases or disorders. Its product candidates are in various stages of development for the treatment of achromatopsia, X-linked retinitis pigmentosa, albinism, and blue cone monochromacy.
– Heat Biologics Inc ($NYSEAM:HTBX)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics to treat serious and life-threatening medical conditions. The company’s market cap as of 2022 is 9.11M and its ROE is 71.6%. Incyte’s main therapeutic areas of focus are oncology and hematology. The company’s most notable products include Jakafi (ruxolitinib), a treatment for myelofibrosis and polycythemia vera; and Iclusig (ponatinib), a treatment for chronic myeloid leukemia.
Summary
Hookipa Pharma Inc. has seen its stock soar on an equity investment of $21.25 million from Gilead Sciences, Inc. This investment highlights the confidence that the latter has in the former’s potential and product portfolio. Analysts believe that this news could be a major step towards driving the stock price of Hookipa Pharma Inc. higher in the long run. The company’s focus on developing innovative therapies for infectious diseases and cancer has caught the eye of many investors.
It is likely that, in the near future, other investors will join Gilead Sciences in providing capital to Hookipa Pharma Inc. in order to benefit from their promising product portfolio. This could be a great opportunity for investors looking for a high-growth stock that can provide a strong return on investment.
